PRF1 and neoplasm: The following are other treatment groups that exhibited stimulatory activities by our analysis: rAd.sT.GM and anti-PD-1, which both enhanced the expression of IL-4 and perforin in tumor; anti-CTLA-4, in which increases of spleen IL-2 and tumor IFN-γ and perforin were detected; anti-PD-1 + anti-CTLA-4, with enhanced tumor IFN-γ expression; rAd.sT.GM + anti-PD-1, in which spleen IL-2, IL-4, and IFN-γ expression and tumor IL-4 and perforin expression were upregulated; and rAd.sT.GM + anti-CTLA-4, in which all targets above were increased except for spleen IL-2 and IFN-γ.